Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes-Reference-Cited by-同舟云学术

Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes

Published:2017-02-03 Issue:1 Volume:56 Page:121-128
ISSN:1355-008X
Container-title:Endocrine
language:en
Short-container-title:Endocrine

Author:

Haddad Robert I.,Schlumberger Martin,Wirth Lori J.,Sherman Eric J.,Shah Manisha H.,Robinson Bruce,Dutcus Corina E.,Teng Angela,Gianoukakis Andrew G.,Sherman Steven I.

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s12020-017-1233-5.pdf

Reference19 articles.

1. L.S. Rosen, VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 10, 382–391 (2005)

2. D. Bose, F. Meric-Bernstam, W. Hofstetter, D.A. Reardon, K.T. Flaherty, L.M. Ellis, Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 11, 373–382 (2010)

3. C. Widakowich, G. de Castro Jr., E. de Azambuja, P. Dinh, A. Awada, Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 12, 1443–1455 (2007)

4. J. Matsui, Y. Yamamoto, Y. Funahashi, A. Tsuruoka, T. Watanabe, T. Wakabayashi, T. Uenaka, M. Asada, E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int. J. Cancer 122, 664–671 (2008)

5. K. Okamoto, K. Kodama, K. Takase, N.H. Sugi, Y. Yamamoto, M. Iwata, A. Tsuruoka, Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 340, 97–103 (2013)

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial;Frontiers in Oncology;2024-07-30

2. Palmoplantar Erythrodysesthesia: An Unusual Side Effect of Lenvatinib;Clinical Dermatology Review;2024-04

3. Utility and optimal management of planned drug holidays during lenvatinib treatment in patients with unresectable differentiated thyroid cancer: a real-world multi-center study;Endocrine;2024-02-27

4. Nonsurgical salvage options for locally recurrent prostate cancer after primary definitive radiotherapy: A systematic review and meta-analysis;International Journal of Surgery;2024-02-09

5. The importance of early-stage blood pressure control in thyroid cancer patients treated with lenvatinib from the perspective of dose intensity;Supportive Care in Cancer;2023-11-29